Understanding peptide reconstitution: concentrations, diluents, and stability windows
The chemistry behind reconstitution choices, and what published stability data actually covers.
EducationCJC-1295
Also known as: Modified GRF 1-29 (without DAC), CJC-1295 DAC
ClassGrowth-hormone-releasing hormone analog
Research statusPreclinical / early human studies
Independent tests2
Studies indexed1
Overview
CJC-1295 is a modified analog of growth-hormone-releasing hormone. The DAC (Drug Affinity Complex) version binds albumin to extend half-life to roughly a week; the non-DAC version acts briefly. Early human studies demonstrated sustained GH and IGF-1 elevation.
Labeling confusion between DAC and non-DAC versions is common in the research-chemical market, and our testing has repeatedly found products mislabeled between the two forms.
Research & Studies
Studies library-
Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults
Demonstrated multi-day GH/IGF-1 elevation from the DAC-modified GHRH analog.
Independent Testing
Testing databaseLaboratory verification of CJC-1295 products across the companies we index.
CJC-1295 PureSci Labs
Purity 97.8% Verified
CJC-1295 NextGen Peptides
Purity 97.9% Verified
Latest Coverage
Ipamorelin and CJC-1295: what stacked GH-axis research actually measures
The synergy claim has real pharmacology behind it — and important measurement caveats.
ScienceTesamorelin: the approved GHRH analog most researchers overlook
A full FDA approval, phase 3 visceral-fat data, and lessons for evaluating its gray-market cousins.
ScienceCommunity Discussions
Forum 23 replies
26 replies
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements